Prostate cancer is the 2nd most common cancer in men worldwide. Based on the results of several recent clinical trials, systemic treatments including hormone inhibitors, docetaxel, cabazitaxel, and PARP inhibitors are being used as standard treatment for patients with metastatic castration-resistant prostate cancer. However, there is insufficient research on salvage therapy for patients with metastatic castration-resistant prostate cancer who have failed standard treatment. In this study, the investigators will evaluate the effectiveness and safety of ifosfamide in castration-resistant prostate cancer by analyzing the treatment outcomes of patients who received ifosfamide/mesna treatment as salvage therapy.
19 years and older adult male
Patients with histologically confirmed prostate cancer
Castration-resistant prostate cancer
ECOG 2 or less
Patients with other primary cancers diagnosed within 3 years other than prostate cancer
Patients with a history of organ transplantation
Hormone sensitive prostate cancer
ECOG 3 or higher
Patients with metastatic castration-resistant prostate cancer
Cohort
Retrospective
Ifosfamide/mesna
DrugIfosfamide 2,500 mg/m2/day for 3 days every 3 weeks with mesna until disease progression
Objective response rate
Summation of complete response partial response based on RECIST version 1.1
Number of patients with Adverse events based on CTCAE
Adverse events based on CTCAE
Overall survival
From date of treatment start to death
Click on the lead sponsor to view all of their trials.
